Introduction: A resurgence of interest in Ayurveda, other traditional systems of medicine, and complementary and alternative medicine (CAM) has resulted from the preference of many consumers for products of natural origin. The potential benefits of plant-based medicines could lie in their high acceptance by patients, and efficacy and safety. The most prevalent users of traditional medicine are individuals who have refractory conditions and nonlife-threatening conditions that may be chronic viz. neurological disorders, arthritis, etc. The second-largest group of users is those struggling with chronic, potentially life-threatening diseases, such as cancer and human immunodeficiency virus/acquired immunodeficiency syndrome, etc. Both groups turn to Ayurveda and traditional system of medicine for a variety of reasons, such as management as the main treatment option and improved immune functioning, overall functioning, and quality-of-life (QoL) by coping with side effects from conventional therapies, and to relieve symptoms related to their illness. The upsurge in use of traditional system among cancer patients warrants evidence of safety and effectiveness for these interventions as concomitant to conventional cancer therapy.
INTRODUCTION
Cancer is the most dreaded disease of the 21st century, and is spreading further with continuance and increasing incidence. Multidisciplinary scientific investigations are making best efforts to combat this disease, but the cure for the disease is still elusive. Management of cancer includes surgery, radiation therapy, chemotherapy, and biological therapy resulting in cure of >50% of patients diagnosed with cancer. The modern approach to the treatment of cancer has reached a plateau. Owing to the importance/benefits of traditional medicine, the World Health Organization (WHO) has included integrative oncology as one of the primary objectives of treatment of cancer besides cure, prevention of recurrence, prolongation of life, rehabilitation, and improvement of QoL.
About 50% of the world's cancer burden is carried by developing countries that ironically have access to only 5% of the resources available to fight the disease. In the developing world, and arguably the developed world, CAM may become an important component of modern oncology, if integrated properly into mainstream medicine. 1 There are many reasons why people living with cancer use traditional systems of medicine like Ayurveda. Accessibility, affordability, tolerability, compromised QoL, and variable success rates are the problem areas of conventional cancer care. In most of these areas, CAM is contributing in one or other ways. According to a survey JDRAS on CAM use in cancer, the most common CAM therapy in use was found to be Ayurvedic treatment. Overall, CAM use was found to be 38.7%. About 60% of patients who were aware of CAM were not using CAM, only 40% aware were using CAM. 2 The physicians who work in integrated clinics that provide both conventional and complementary services may refer patients to these clinics for pain management, to learn adaptive coping strategies, to manage chronic and serious medical illness, and to manage cancer-related symptoms. Diseases mentioned in Ayurvedic texts like arbuda, granthi, gulma, adhyarbuda, apachi, asadhya-vrana, etc., can be correlated with neoplasms, solid tumors, and/ or malignancies along with some asadhya conditions (conditions with bad-to-worst prognosis) of various diseases like udara, kumbha-kamala, halimaka (possibilities of hepatobiliary malignancies), jvara, rajayakshma, pandu (leukemia), etc. However, if one tries to search for the exact picture of say a sarcoma or leukemia and other such malignant conditions as understood and narrated in biomedical literature from Ayurvedic texts, the exercise would be futile. Instead, it is quite pragmatic to apply the Ayurveda principles, which govern the state of health and disease, i.e., tridoshas (three beholders and vitiators of body), saptadhatu (seven tissues), agni (digestion and metabolism), nidana-panchaka (penta-dimensional diagnostic instrument), shat-kriyakala (six stages of morbidity), etc., to certain types of cancer and it will surely open the gates for the diagnosis and exploring potential treatment modalities to handle the same. 3 In current practices, cancer management through Ayurveda is intended as add-on to conventional treatment; however, stand-alone mode also has shown encouraging outcomes. The social role of use of traditional systems of medicines among people suffering with cancer has been examined; some studies have examined the effectiveness of Ayurveda on symptom management and improvement of QoL. Patients turn to AYUSH systems for a variety of reasons, such as to improve immune functioning, overall functioning, QoL, and to cope with side effects from conventional therapies, to relieve symptoms as stand-alone or add-on management, or as an add-on to conventional management. Ayurveda is found to contribute significantly in most of these issues and it has been seen practically in various published scientific clinical studies and practices. The upsurge in use of CAM among cancer patients warrants evidence of safety and effectiveness for these interventions as concomitant to conventional cancer therapy. Clinical evidences for phytochemicals as anticancer therapy are available; however, few references of systematic reviews or meta-analyses of Ayurveda or plant-based interventions for cancer are found. There is a need for such reviews to generate evidence to formulate Integrative Ayurveda Oncology treatment protocols.
MATERIALS AND METHODS

Data Sources
Articles published in different peer-reviewed journals were analyzed for this study. PubMed, AYUSH Research Portal, Google Scholar, and Google were searched during the period of May to June 2017, with specific keywords along with print journals, periodicals, and reports. 
Search Terms and Strategy
Study Selection
Inclusion criteria were use of Ayurveda interventions: herbal, polyherbal, herbomineral, metallic preparations with the intent of cure or as add-on; in any type of cancer; any clinical study type. The exclusion criteria were laboratory or nonhuman experiments, healthy volunteer studies of anticancer herbs, and unpublished studies.
OBSERVATIONS
The PubMed search resulted in 1,653 citations, AYUSH Research Portal yielded 42 citations, and Google Scholar yielded 3,000 citations. However, 68 articles were retrieved after applying the inclusion, exclusion criteria, and others were excluded (Fig. 1) .
About 32 out of the 68 are the RCT studies on ginger, honey, and turmeric, and these data are presented in Tables 1 to 3 . The remaining 36 studies are categorized based on the study design (Table 4) .
In these studies, it was observed that the Ayurvedic interventions were used to reduce the side effects of conventional therapy and used in combinations instead of single Ayurvedic interventions (Table 5) . 
DISCUSSION
Studies Related to Ginger
A total of 12 clinical research works are found using ginger in various types of cancer patients (1473). Most of the works were randomized double-blinded placebocontrolled studies to evaluate the efficacy of ginger (root powder/extract) in CINV. In all studies, ginger was used as oral administration except in two studies where it was used as aromatherapy for CINV and salivary gland damage for patients undergoing radioactive iodine (RAI) therapy with differentiated thyroid cancer (DTC). Ginger has shown significant results in terms of scores, intensity, and frequency of CINV. A 5-day aromatherapy treatment using either ginger essential oil or fragrancematched artificial placebo (ginger fragrance oil), which was instilled in a necklace was used in 60 breast cancer patients. Although evidence derived from this study is not sufficiently convincing that inhaled ginger aromatherapy is an effective complementary therapy for CINV, the findings for health-related QoL (HRQoL) were, however, encouraging with significant improvement in several domains. Thus, ginger is sufficiently evaluated for its antiemetic effect in CINV in cancer management (Table 1) .
Studies Related to Honey
Totally 16 clinical studies were found in cancer patients, where honey was used alone or mixed with others as supplement. Most of these studies were RCTs with a total of 1,093 cancer subjects involved. These studies were focused on with Head and Neck cancer patients, who developed treatment-induced oral mucositis. 11 studies, with one prophylactic study, and studies about malignant wound (1), burn cases (1), radiation-induced burns in breast cancer patients (1), and cancer treatmentinduced neutropenia (2) . Honey was used as local application in most of the studies (14) for oral mucositis either alone or in combination with turmeric/coffee/olive oil, propolis, beewax). It was compared with various other established treatment drugs other than placebo (2), like normal saline (2), lignocaine (1), betamethasone solution (1 honey + coffee), or silver-coated bandages (2) . In one study, honey was used alone and in combination with olive oil-propolis extract, and beeswax (HOPE). Three equal treatment groups: Honey, HOPE (mixture of honey), and control groups were evaluated for outcomes in acute lymphoblastic leukemia (ALL) and grade II/ III chemotherapy-induced mucositis. Honey was used internally in one study of febrile neutropenic patients of ALL. Dietary intervention consisted of honey in a dose of 2.5 gm/kg body weight per dose twice weekly for 12 weeks. It showed marked improvement in children in their hematologic parameters. In other studies, where honey (Life Mel Honey, LMH) was used internally in neutropenic patients treated with chemotherapy for primary or metastatic disease; there was no recurrence of neutropenia after LMH intake and no need for treatment with colony-stimulating factors (CSFs) in 12 (40%) patients. Hemoglobin levels remained >11 gm/dL during LMH intake in 19 (64%) patients. Eight (32%) patients reported improvement in QoL (Table 2) .
In case of oral mucositis treatment outcomes, honey showed significant improvement in symptoms and improved QoL of patients as compared with control Occurrence of grade III dermatitis was lower in the cohorts using VTC and was statistically significant (p < 0.01). Additionally, follow-up observations 2 weeks after the completion of radiotherapy also showed a reduced degree of radiodermatitis in cohorts applying VTC, which was significant (p = 0.015).
JDRAS
Rao et al., 2014
Single-blind, 
Radiation
Therapy Oncology Group grading system Group using turmeric as a mouthwash had delayed and reduced levels of radiation-induced oral mucositis and was statistically significant at all time points (p < 0.001 to p < 0.0 001). Additionally, the cohorts using turmeric had decreased intolerable mucositis (p < 0.001) and lesser incidence of treatment breaks in the first half of the treatment schedule before 4 weeks (p < 0.01) and reduced change in body weight (p < 0.001) arm. In a study about malignant wounds and advanced cancer, no statistically significant difference was noted between group I (honey-coated bandages) and group II (silver-coated bandages) with respect to wound size, degree of cleanliness, exudation, malodor, and wound pain. While in a study of radiation-induced burn following breast conservative surgery, honey was used as treatment supplement. Group I received standard burn treatment (control group). Group II received additionally 400 mg Pentoxifylline twice daily. Group III received the same treatment as group II with added topical purified honey ointment. Honey was found to be effective in pain management and also in faster recovery in 74% cases.
Studies Related to Turmeric
Out of four studies, three were found to be RCTs wherein the turmeric was used locally in radio-dermatitis (2), as gargle in radiation induced oral mucositis (1) and orally turmeric powder in CML (1) . Topical application of turmeric containing cream has shown significant reduction in grades of dermatitis at all-time points. Turmeric as a mouthwash had delayed and reduced the levels of radiation-induced oral mucositis and was statistically significant at all-time points. Additionally, turmeric had decreased intolerable mucositis and lesser incidence of treatment breaks in the first half of the treatment schedule before 4 weeks. Local application of turmeric and honey on treatment induced oral mucositis was effective. In CML study, Nitric oxide levels were found to be significantly decreased in both the groups, but more significantly in group receiving turmeric powder along with Imatinib for six weeks in CML. (Table 3 ).
OTHER 36 STUDIES
Randomized Controlled Trials
A total of 214 patients with breast carcinoma receiving adjuvant or neoadjuvant chemotherapy were treated with
JDRAS
Maharishi Amrita Kalash (MAK), an Ayurvedic compound.
There was a significant reduction in toxicities observed in the MAK group throughout chemotherapy cycles. Poor performance status was prevented by concomitant administration of MAK along with chemotherapy. No overgrowth of tumors occurred in the group treated with neoadjuvant chemotherapy receiving MAK. 36 A total of 78 patients, who were treated for head and neck cancers, were divided into two groups, treatment and control groups. Patients in the intervention group (n = 38) received Varunadi Ghritha, 5 gm twice daily for 1 year and followed up to 2 years. In the treatment group, mean percentage increase in CD3, CD19, and CD16 positive cells were significantly higher compared with the control group indicating an immunomodulatory effect of the study compound. 37 In a prospective open-labeled RCT conducted on 49 cancer patients undergoing six cycles of 70 mg/m 2 cisplatin-based regimens, divided into two groups, a control group (I) in which 28 patients received cisplatin without cystone supplement and an experimental group (II) in which 21 patients received cisplatin with cystone supplement, a polyherbal preparation. At the end of the study, mean levels of serum creatinine, blood urea, and serum cystatin C were significantly lower, whereas creatinine clearance was significantly higher in group II compared with group I. Grading of acute kidney injury according to Common Terminology Criteria for Adverse Events revealed significantly better renal status among patients in group II "grades 0 and 1 in 76 and 24% of the patients respectively," compared with group I "grades 0, 1, and 2 in 36, 32, and 32% of the patients respectively."
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Nonrandomized, Placebo-controlled Trial
A trial was undertaken with 108 cervical cancer patients (54 patients as study group and remaining 54 patients as control group). The study group patients received only supportive Ayurvedic patent and proprietary (P&P) remedies as Liv 52, Septilin, Geriforte, Lukol, Gasex, and Herbolax, whereas the control group was managed with conventional allopathic medicaments along with external irradiation. Evaluation at the end of the study revealed that the study group patients maintained an excellent hematobiochemical profile, which helped them to achieve a much better treatment response than the control group. About 55% of cervical cancer cases had 3 years' diseasefree survival by consuming herbal medicines along with external tele-cobalt irradiation and brachytherapy. 39 Phase I: 100 patients with proven head and neck cancer undergoing radiotherapy were divided into two groups. Trial I group of 50 patients received Geriforte, 2 tabs, b.i.d. and control was a group of the remaining 50 on a placebo. Phase II: 50 patients in postradiotherapy phase, 25 were on Geriforte, 2 tabs. b.i.d., and the other 25 on a placebo. Evaluation in both phases was done after 4 to 5 weeks of therapy on complaints, such as lack of interest in surroundings, depression, insomnia, and lack of appetite, lack of a feeling of wellbeing, fatigability, and anxiety. Nearly one-thirds of patients in Phase I and three-fourths in Phase II reported subjective improvement on Geriforte administration. 40 
Nonrandomized Multiple Arm Trials
A total of 250 cancer cases of either sex, different types, sites stages were treated with a formulation consisting of Bhallataka, Rohitaka, Madhuyashthi, and Tamra Bhasma as stand-alone and as add-on/adjuvant therapy to radio/ chemotherapies. Significant gain in weight, increase in survival period, and improved immune status were observed. The side effects of chemotherapy like nausea, anemia, and hairfall were decreased. 41 A total of 80 cancer patients were divided into four groups. The first was control group, Ayurvedic-Oncocare capsule was given in the second group, third group received only Pranic healing techniques, and group four received both Oncocare capsule and Pranic healing techniques. There was a highly significant improvement in the fourth group, i.e., combination of herbal formulation along with stress-management techniques. 42 A total of 67 cancer patients of various types who were undergoing six cycles of chemotherapy were given Mauktikyukta Kamdudha, Mauktikyukta, Praval Panchamruta, and Suvarna bhasmadi formulation for 16 weeks and were observed for a period of 6 months. There was a significant effect in reducing the toxic sideeffects of chemotherapy drugs, such as nausea, loss of appetite, constipation, and fatigue. 43 A total of 75 cancer patients undergoing radiotherapy were randomly divided into four groups: group I with local application of Yashtimadhu (Glycyrrhiza glabra L.) powder and honey in the oral cavity for few minutes prior to radiotherapy along with oral intake of Yashtimadhu Ghrita; group II with only local application of the Yashtimadhu powder and honey in the oral cavity; group III patients administered with only local application of honey in the oral cavity; and group IV on conventional modern medication-controlled group. All these patients under the four groups had received radiotherapy and chemotherapy for a maximum duration of 7 weeks. The intensity of radiation-and chemotherapy-induced mucositis was reduced to a great extent by the trial drug. 44 
Nonrandomized, Controlled Trials
A total of 100 breast cancer patients undergoing chemotherapy were given Ashwagandha (Withania somnifera (L.) Dunal) root extract at a dose of 2 gm every 8 hours, throughout the course of chemotherapy. Significant improvement in cancer-related fatigue and QoL was found in comparison with the control group. 45 A total of 50 breast cancer patients undergoing chemotherapy were given Ashwagandha (Withania somnifera (L.) Dunal) root extract at a dose of 2 gm every 8 hours, throughout the course of chemotherapy. There was a trend for longer survival in the patients treated with W. somnifera (L.) Dunal root extract plus chemotherapy along with positive effect on fatigue and improvement in QoL in patients. 46 A total of 36 cancer patients were divided into two groups, groups I and II. In group I, the patients were treated with radiotherapy and chemotherapy along with adjuvant Rasayana Avaleha (RT + CT + RA), while in group II, only radiotherapy and chemotherapy (RT + CT) were given as the control group. After assessing the results, it was observed that Rasayana Avaleha gave better results in controlling the adverse effect of chemotherapy and radiotherapy in comparison with the control group. 47 A total of 30 patients of oral carcinoma were divided into three groups with 10 patients in each group. Comparative study was done between three groups by giving radiotherapy alone in one group and Ayurvedic formulation + radiotherapy in the other two groups at different intervals. Results suggested that there was significant reduction of the side effects in the patients who were taking Ayurvedic formulation along with radiotherapy. 48 An indigenous P&P formulation-Carsinolyt [avaleha (electuary) and Ghana satva (consolidated extract)] was evaluated to prevent side effects of radiotherapy on 40 patients; group I patients were given Carsinolyt and radiotherapy simultaneously, whereas group II patients were given radiotherapy only. The results achieved were encouraging with improvement of 56.62% in mucosal reactions, 37.5% in hematological status, 18.18% in pain, 8.33% in salivary reactions, and 21.42% in skin reactions. 49 In a controlled clinical trial, a liquid Ayurvedic (herbal) preparation (Misraka sneham) was compared with a conventional laxative tablet (Sofsena) in the management of opioid-induced constipation in patients with advanced cancer. Although there was no statistically significant difference in the apparent degree of laxative action between the two, the results indicate that the small volume of the drug required for effective laxative action, the tolerable taste, the once-daily dose, the acceptable side effect profile, and the low cost make Misraka sneham a good choice for prophylaxis in opioid-induced constipation. 50 The effect of an indigenous medical preparationBrahma Rasayana (BR)-on the hematopoietic protection in cancer patients undergoing radio in association with chemotherapy was studied. Administration of BR accelerated the recovery of the hematopoietic system as seen by a rapid rise in total leukocytes. Both lymphocytes and neutrophils were significantly increased by Rasayana treatment. The Rasayana treatment also made serum lipid peroxidation decrease confirming its capacity of reducing oxidative stress induced by cancer treatment.
51
Single-Arm Trial
A total of 84 patients with cancer of various organs like tongue, stomach, breast, and lungs were treated with Bhallataka (Semecarpus anacardium L.f. ), which resulted in improvement in general condition and symptom relief in 50% patients. 52 A total of 43 patients were given Swarna Bhasma (SB) for 1 year; 17 patients showed response. The response was best in rectal cancer group 70% (7/10). Nearly 41.02% patients survived for 1 year after treatment, but, after 5 years, this came down to 15.38%.
53
Case Series
Two patients with oral cancer were treated with "Huma" a polyherbal therapy derived from various important Ayurvedic herbs viz. Nimba (Azadirachta indica), Haridra (Curcuma longa), Amalaki (Embelica officinalis), Tulasi (Ocimum sanctum), Bhallataka (Semecarpus anacardium), Guduchi (Tinospora cordifolia), etc. Complete regression of the tumor/lesion was observed in one patient and marked remission in other. One patient completed over 7 years' disease-free survival. In the other patient, the disease relapsed after stoppage of therapy and the patient survived for 15 months. 54 A total of 75 cases of various hepatobiliary disorders in this series included 60 patients of cholecystolithiasis, 10 patients of choledolithiasis, and 5 patients of cancer of gall bladder who were operated upon (cholecystectomy). Arogyawardhani was given in the dose of 1 gm B.D. after meals for 45 to 60 days after cholecystectomy. Arogyawardhani has significantly lowered the level of serum bilirubin, thymol turbidity, alkaline phosphatase, and serum proteins. The use of Arogyawardhani is advocated in the patients of postcholecystectomy syndrome and in other cases where there is dearrangement of liver functions. 55 Arbudaharana rasayana, a herbo-mineral compound formulation (Anubhuta yoga ) practiced by traditional healers of Orissa as a folklore medicine, for the management of Arbuda was studied clinically in 10 patients of nonoperable malignancy of different regions of body like scalp, vagina, esophagus, bladder, and oral cavity. The drug was given in powder form, 5 gm twice a day, orally with lukewarm water for 2 months. Symptomatic relief was observed in treated patients with overall improvement in QoL. No adverse effect of drug was observed. 56 Nine female breast cancer patients who had undergone chemotherapy and had completed primary curative treatment 1 to 12 months earlier were recruited in a 4-month individualized intervention that included diet, lifestyle, yoga, and marma (similar to acupressure). Every other participant was selected for semistructured interviews at baseline and completion. The authors concluded that the whole system Ayurvedic intervention appeared to lead to an enhanced awareness of the body's innate healing mechanisms and a strong motivation to use them for self-care. The holistic nature of the intervention facilitated integration of mind and body resulting in a sense of increased vitality. These findings correlated with quantitative QoL measurements indicating improved global health.
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Case Reports
A 47-year-old diabetic male of high-risk acute myeloid leukemia (AML)-M3 (type of Blood cancer) was treated on allopathy regimen, but had recurrence. He was treated with Navajeevan, Kamadudha rasa, and Keharuba pishti for period of 6 years, got complete remission, and was disease-free for 13 years. This was a pilot Ayurvedic study conducted by the Central Council for Research in Ayurveda and Siddha, Ministry of AYUSH.
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A 16-year-old boy with AML (a type of blood cancer) with relapse despite allopathy treatment was treated with Ayurvedic therapy (Navjeevan, Valapani, Kamdhuda, Prak-20) for 5 years, and this resulted in 12 years of disease-free survival. 59 A case of laryngeal carcinoma was treated using rasayana therapy (Navjeevan rasayana (A compound formulation containing Abhraka bhasma, Shuddha Gandhaka, Vanga bhasma, Shuddha Parada, Shuddha Haratala, Tamra bhasma, Swarna bhasma, Hirakbhasma) along with other Ayurvedic formulations like Tribhuvankirti, Shwas kuthar rasa, powder of Solanum xanthocarpum L., Saussurea lappa (Falc.) Lipsch, tankan, and Sitopaladi churna along with radiotherapy. Within 4 weeks of treatment, the patient's voice became clear and he retained his physical fitness; there was complete tumor response along with optimization of laryngeal functions like voice, breathing, and swallowing without any adverse effects of radiotherapy. After 8 months of treatment, computed tomography scan was repeated, which showed total clearance of the tumor and he was asymptomatic, healthy with absolutely normal voice. 60 A case of colon cancer was treated with rasayana therapy postsurgery and adjuvant chemotherapy. Rasayana therapy included navjeevanrasayana, tamrabhasma, swarnabhasma, hirakbhasma along with Ayurvedic formulations like prawal panchamrut, kamdudha, lashunadiwati, powders of Bilwa (Aegal marmelos), kutaj (Holereana antidysentrica), aamalki (Phallyanthus embelica) with agni rasayana, sutendrarasayana and pranwallabhrasayana. Within 4 weeks of treatment, patient's appetite became normal and he retained his physical fitness. Thereafter, he underwent chemotherapy. All the cycles of chemotherapy were well tolerated by the patient, and he completed the prescribed schedule of chemotherapy. After chemotherapy, patient was exclusively on Ayurvedic rasayana therapy. Patient is surviving disease-free for 4 years with excellent QoL.
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A 62-year-old case of hepatocellular carcinoma was treated with a holistic interdisciplinary approach, i.e., modern medicine treatment followed by Ayurveda treatment and Yoga. Decoction (nimba, guduchi, sadabahara, apamarga, nagarmotha, shirisha, tulasi), rasa aushadhi/ bhasma (Hemabhraka, Tamra sindoora, Vangabhasma, Vaikrantabhasma, Pushkrajabhasma, Manikyapishti), pippalirasayana, tamalakyadi syrup was given. This treatment has shown improvement in appetite, food intake, and a feeling of well-being. 62 A herbo-mineral formulation (LAS-01) was employed on a case of non-Hodgkins lymphoma after chemotherapy and radiation with no remedial effects. In a short span of treatment, marked clinical and radiological effects were observed. The patient felt improvement in comparison of modern treatment in healing the nasal wound and QOL. 63 A 62-year-old male patient with synchronous renal cell carcinoma and leiomyosarcoma was admitted with severe pain. However, for 2 months, the patient came to the clinic in good condition free of pain. The patient reported outpatient self-treatment with seven leeches (Hirudo medicinalis) to the lumbar region in the interim that resulted in complete healing of pain.
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A 4-year-old patient was treated with an Ayurvedic formulation and majjabasti to get the bone marrow transplant effect. The patient got significant result with the help of Ayurvedic medicines.
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STUDIES RELATED TO PREVENTIVE INTENTION
Nonrandomized, Placebo-controlled Trial
A total of 21 diagnosed cases positive for human papillomavirus (HPV)16 infection without or with low-grade squamous intraepithelial lesion (LSIL) or inflammation were assigned to receive intravaginal, topical application of either "Praneem" tablet (a polyherbal formulation) or placebo for 30 days excluding the days of menstrual period and were evaluated for persistence of HPV infection. The results showed that a 30-day intravaginal application of the "Praneem" can result in elimination of HPV infection from the uterine cervix along with marked improvement in clinical symptoms. 66 In a study conducted in collaboration with ICMR, 35 female patients enrolled were assigned alternatively to receive intravaginal capsules of "BASANT," two capsules (250 mg each) each night or two placebo capsules for 30 days, excluding the days of menstrual period, and they were evaluated for the presence or absence of HPV16 in cervical cells. The "BASANT" was formulated with curcumin from Curcuma longa (haridra), purified extracts of Emblica officinalis L (Amalaki), Azadirachta indica A.juss. 
Single-arm Trial
A total of 21 female patients with persistent cervical LSIL, a precancerous stage were treated with Haridra (Curcuma longa) capsules for 12 weeks. It was found to arrest or regress LSIL in Pap smears and colposcopy, with reduction in the circulating interleukin 6 levels. 68 A total of 34 teenager boys of the 13-to-19-year-old age group of North India with precancerous lesions in the mouth were advised indigenous mouth rinse (triphala). Triphala was found to have great potential for reversal of these lesions. 69 A total of 45 patients of recently diagnosed oral submucous fibrosis (OSMF) were advised to mix 1 gm of turmeric powder and 1 gm of tulsi powder in glycerin to make a paste. The patients were instructed to apply this paste all over the oral mucosa 4 to 5 times per day and not to eat or drink anything for the next 15 minutes. Statistically highly significant (p < 0.001) results were obtained in burning sensation and mouth opening. 70 A total of 24 patients with OSMF were administered Erandabhrishta haritaki powder 5 to 10 gm initial 3 days at bed time for koshthashuddhi (mild purgation), followed by Shadabindu taila nasya (errhine therapy) 4 to 8 drops in each nostril for 5 days. After that, Pratisarana (external application), kavala (gargling), and rasayana yoga were administered twice a day simultaneously for 60 days. Statistically highly significant (p < 0.001) results were found in symptoms, such as burning sensation of mouth, intolerance to spicy food, dryness of mouth, pain while opening the mouth, and clinically marked improvement was observed in decreased taste.
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CONCLUSION
Emphasis on generating tangible evidence is essential to demonstrate efficacy of stand-alone Ayurveda interventions in cancer backed by published case reports.
JDRAS
Well-designed studies with adequate sample sizes are required for validation of the leads from Ayurveda as stand-alone clinical studies. Many RCTs and casecontrol studies have generated reasonably good evidence for Ayurveda and plant-based interventions as add-on concomitant to conventional cancer treatment to combat its toxicities, particularly, radiation mucositis and chemotherapy-induced nausea and vomiting and overall fatigue. For effective dissemination of merits of Ayurveda for prevention and management of cancer, the published information may be suitably made available to all stakeholders, such as academicians, clinicians, and researchers through Web portals. Further, these portals may be linked with existing the AYUSH Research portal being maintained by CCRAS at http://ayushportal.nic.in.
